Janux Therapeutics (NASDAQ:JANX) Issues Earnings Results

Janux Therapeutics (NASDAQ:JANX) issued its earnings results on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.13, FiscalAI reports. The company had revenue of $9.29 million during the quarter, compared to analysts’ expectations of $8.03 million.

Janux Therapeutics Trading Down 11.7%

JANX stock traded down $2.12 during midday trading on Thursday, hitting $16.06. 893,121 shares of the company’s stock were exchanged, compared to its average volume of 755,955. The business has a 50-day simple moving average of $17.52 and a two-hundred day simple moving average of $15.39. The stock has a market capitalization of $981.91 million, a PE ratio of -9.79 and a beta of 2.44. Janux Therapeutics has a 1-year low of $12.12 and a 1-year high of $35.34.

Analysts Set New Price Targets

JANX has been the topic of several analyst reports. Stifel Nicolaus set a $35.00 price target on Janux Therapeutics in a report on Friday, August 7th. HC Wainwright reissued a “buy” rating on shares of Janux Therapeutics in a report on Monday, October 19th. TD Cowen upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Guggenheim reduced their target price on shares of Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Finally, Wolfe Research raised shares of Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 target price on the stock in a research note on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Janux Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.46.

About Janux Therapeutics

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.